|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
B; D , 3rd trimester
|
|
INDICATIONS:
|
|
Ankylosing spondylitis |
|
Arthritis, gouty |
|
Arthritis, osteoarthritis |
|
Arthritis, rheumatoid |
|
Bursitis |
|
Patent ductus arteriosus |
|
Tendonitis, shoulder |
| |
|
|
SIDE EFFECTS:
|
|
abdominal pain |
|
agranulocytosis |
|
anaphylactic shock |
|
anaphylactoid reactions |
|
anemia |
|
aplastic anemia |
|
apnea |
|
aseptic meningitis |
|
azotemia |
|
constipation |
|
depression |
|
diarrhea |
|
dizziness |
|
dyspepsia |
|
dysphagia |
|
edema |
|
elevated hepatic enzymes |
|
esophageal stricture |
|
esophageal ulceration |
|
esophagitis |
|
exfoliative dermatitis |
|
fatigue |
|
flatulence |
|
fluid retention |
|
gastritis |
|
GI bleeding |
|
GI perforation |
|
headache |
|
heart failure |
|
hemolytic anemia |
|
hepatitis |
|
hyperkalemia |
|
hypertension |
|
hypoglycemia |
|
hyponatremia |
|
infection |
|
interstitial nephritis |
|
intraventricular hemorrhage |
|
jaundice |
|
malaise |
|
melena |
|
nausea/vomiting |
|
nephrotic syndrome |
|
odynophagia |
|
oliguria |
|
pancytopenia |
|
peptic ulcer |
|
peripheral edema |
|
platelet dysfunction |
|
pyrosis (heartburn) |
|
rash (unspecified) |
|
renal papillary necrosis |
|
retinopathy |
|
skin irritation |
|
Stevens-Johnson syndrome |
|
tenesmus |
|
thrombocytopenia |
|
tinnitus |
|
toxic epidermal necrolysis |
|
urticaria |
|
vertigo |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
acute bronchospasm |
|
alcoholism |
|
anemia |
|
anticoagulant therapy |
|
asthma |
|
bone marrow suppression |
|
breast-feeding |
|
chemotherapy |
|
children |
|
coagulopathy |
|
corticosteroid therapy |
|
dehydration |
|
dental disease |
|
dental work |
|
depression |
|
diabetes mellitus |
|
driving or operating machinery |
|
edema |
|
elderly |
|
GI bleeding |
|
GI disease |
|
heart failure |
|
hematological disease |
|
hemophilia |
|
hemorrhoids |
|
hepatic disease |
|
hypertension |
|
immunosuppression |
|
intramuscular injections |
|
jaundice |
|
labor |
|
nasal polyps |
|
neutropenia |
|
Parkinson's disease |
|
peptic ulcer disease |
|
pregnancy |
|
renal disease |
|
renal failure |
|
renal impairment |
|
rheumatoid arthritis |
|
seizure disorder |
|
sepsis |
|
surgery |
|
systemic lupus erythematosus (SLE) |
|
thrombocytopenia |
|
tobacco smoking |
|
ulcerative colitis |
|
|
ADULT DOSE:
|
|
Antirheumatic (nonsteroidal anti-inflammatory) -Oral, initially 25 or 50 mg two to four times a day; if well tolerated, the dosage per day may be increased by 25 or 50 mg at weekly intervals until a satisfactory response is obtained or up to a maximum dose of 200 mg per day. After a satisfactory response has been achieved, dosage should be reduced to the lowest dose that provides continuing control of symptoms.
Note: In acute flare-ups of rheumatoid arthritis, dosage may be increased by 25 or 50 mg daily, as needed and tolerated.
For those arthritic patients who have persistent night pain and/or morning stiffness, up to 100 mg of the total daily dose may be given at bedtime. Lower bedtime doses may not provide adequate symptomatic relief.
A daily dose of less than 75 mg may not be effective in active inflammatory disease.
A daily dose of more than 150 to 200 mg may increase the risk of adverse effects without providing additional clinical benefit.
Antigout agent-Oral, 100 mg initially, then 50 mg three times a day until pain is relieved, with the dosage then being reduced until medication is discontinued.
Anti-inflammatory (nonsteroidal) -75 to 150 mg per day in three or four divided doses.
Note: When used to treat conditions not requiring chronic therapy, such as acute bursitis or tendinitis of the shoulder, indomethacin should be discontinued when symptoms of inflammation have been controlled for several days. The usual length of treatment is 7 to 14 days.
[Antipyretic ] -Oral, 25 or 50 mg three or four times a day. |
|
MAXIMUM ADULT DOSE:
|
|
Oral, 200 mg a day.
|
|
PEDIATRIC DOSE:
|
|
Antirheumatic (nonsteroidal anti-inflammatory) -Oral, 1.5 to 2.5 mg per kg of body weight per day, administered in three or four divided doses, up to a maximum of 4 mg per kg of body weight per day or 150 to 200 mg per day, whichever is less. After a satisfactory response has been obtained, dosage should be reduced to the lowest dose that provides continuing control of symptoms. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|